NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

自動注射器的全球市場

Autoinjectors

出版商 Global Industry Analysts, Inc. 商品編碼 893773
出版日期 內容資訊 英文 189 Pages
商品交期: 最快1-2個工作天內
價格
自動注射器的全球市場 Autoinjectors
出版日期: 2021年04月01日內容資訊: 英文 189 Pages
簡介

本報告提供全球自動注射器市場相關調查分析,提供市場概要,主要企業,市場趨勢·促進因素,全球市場預測,各地區市場分析,競爭情形相關的系統性資訊。

第1章 簡介,調查手法,調查範圍

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢·促進因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
    • 美國
    • 加拿大
    • 日本
    • 中國
    • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他的歐洲
    • 亞太地區
    • 澳洲
    • 印度
    • 韓國
    • 其他的亞太地區
    • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他南美
    • 中東
    • 伊朗
    • 以色列
    • 沙烏地阿拉伯
    • UAE
    • 其他中東
    • 非洲

第4章 競爭

  • ABBVIE
  • ANTARES PHARMA, INC.
  • CONSORT MEDICAL PLC
  • ELI LILLY AND COMPANY
  • HASELMEIER GMBH
  • MYLAN NV
  • OWEN MUMFORD
  • SHL GROUP
  • TEVA PHARMACEUTICAL INDUSTRIES
  • YPSOMED AG
  • ALK-ABELLO AS
  • AMNEAL PHARMACEUTICALS
  • APTARGROUP, INC.
  • 旭化成
  • ASCENDIS PHARMA A/S
  • ASTRAZENECA PLC
  • ATS AUTOMATION TOOLING SYSTEMS INC.
  • BAUSCH HEALTH COMPANIES INC.
  • BAYER AG
  • BD MEDICAL - PHARMACEUTICAL SYSTEMS
  • BIOGEN INC.
  • BIOMARIN PHARMACEUTICAL
  • BIOPROJET PHARMA
  • BRISTOL-MYERS SQUIBB COMPANY
  • CAMBRIDGE CONSULTANTS
  • CELLTRION HEALTHCARE
  • CHUGAI PHARMACEUTICAL
  • CINNAGEN
  • CREARE
  • CROSSJECT SA
  • DONGBAO ENTERPRISE GROUP
  • DR. REDDY'S LABORATORIES LTD.
  • Eisai
  • EMD SERONO
  • EMERGENT BIOSOLUTIONS
  • F. HOFFMANN-LA ROCHE LTD.
  • FERRING INTERNATIONAL CENTER SA (FERRING PHARMACEUTICALS)
  • GENENTECH, INC.
  • GERRESHEIMER AG
  • GILEAD SCIENCES, INC.
  • IPSEN GROUP
  • JCR PHARMACEUTICALS
  • JIANGSU DELFU MEDICAL DEVICE
  • 協和麒麟
  • LINCOLN MEDICAL
  • MERCK & CO., INC.
  • MERCK KGAA
  • MYLAN PHARMACEUTICAL PVT.
  • NEMERA
  • NGM BIOPHARMACEUTICALS
  • Nipro
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PALATIN TECHNOLOGIES
  • PFIZER, INC
  • PHILLIPS-MEDISIZE, A MOLEX COMPANY
  • PORTESCAP
  • REGENERON PHARMACEUTICALS, INC.
  • SANDOZ INTERNATIONAL GMBH
  • SANOFI SA
  • SCHOTT AG
  • SCHREINER GROUP GMBH & CO. KG
  • 鹽野義製藥
  • 大日本住友製藥
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • Terumo Corporation
  • UCB SA
  • US WORLDMEDS
  • VITRONIC DR.-ING. STEIN BILDVERARBEITUNGSSYSTEME GMBH
  • WEST PHARMACEUTICAL SERVICES
  • XERIS PHARMACEUTICALS
  • 大協精工
  • ENBREL
  • MEDAC GMBH
  • MERIDIAN MEDICAL TECHNOLOGIES, INC.
  • NUANCE DESIGNS OF CT, LLC
  • ONE WORLD DESIGN & MANUFACTURING GROUP, LLC
  • OVAL MEDICAL TECHNOLOGIES LTD.
  • RAVIMED
  • SHL MEDICAL AG
  • TEAM CONSULTING
  • UNION MEDICO APS
  • ZION CLINICAL PHARMACY
  • AGUETTANT
  • AGUETTANT LABORATORY
  • ANDROSYSTEMS
  • CHANGZHOU DELFU TECHNOLOGY
  • CHEMPROTECT.SK S.R.O.
  • AKTIVAX, INC.

第5章 相關調查

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP10421

Abstract:

Global Autoinjectors Market to Reach $118.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Autoinjectors estimated at US$35.1 Billion in the year 2020, is projected to reach a revised size of US$118.6 Billion by 2027, growing at a CAGR of 19% over the analysis period 2020-2027. Rheumatoid Arthritis, one of the segments analyzed in the report, is projected to record a 20.8% CAGR and reach US$43.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Multiple Sclerosis segment is readjusted to a revised 18.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $9.5 Billion, While China is Forecast to Grow at 24.1% CAGR

The Autoinjectors market in the U.S. is estimated at US$9.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$28 Billion by the year 2027 trailing a CAGR of 24.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.7% and 17.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Anaphylaxis Segment to Record 18.1% CAGR

In the global Anaphylaxis segment, USA, Canada, Japan, China and Europe will drive the 17.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.4 Billion in the year 2020 will reach a projected size of US$13.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$17.3 Billion by the year 2027, while Latin America will expand at a 19.4% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company
  • Consort Medical PLC
  • Eli Lilly and Company
  • Haselmeier GmbH
  • Mylan NV
  • Owen Mumford Ltd.
  • SHL Group
  • Teva Pharmaceutical Industries Ltd.
  • Ypsomed AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Rapid Shift from Self-Injectors to Autoinjectors for Easy and Safe Administration of Drugs Drives Demand
    • North America: The Largest Market for Autoinjectors
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Targeted Therapies such as Cancer, Rheumatoid Arthritis, Multiple Sclerosis and Diabetes: A Strong Growth Driver
    • EXHIBIT 1: Number of New Cases of Cancer Worldwide for the Years 2012, 2015, 2020, 2025 and 2030
    • EXHIBIT 2: Diabetes Prevalence in the Age-Group of 20-79 Years in Millions by Region for the Years 2018, 2021 and 2025
    • EXHIBIT 3: Global Injectable Drug Delivery Market: Revenues in US$ Billion for the Years 2016, 2018, 2020, 2022 and 2024
    • Rising Incidence of Anaphylaxis and Increased Prescription Rate of Epinephrine Autoinjectors Boosts Market Demand
    • Increasing Number of Regulatory Approvals for Autoinjectors in Various Diseases
    • Generic Autoinjectors Take Center Stage
    • Patent Expiry of Biologics to Drive the Demand for Biosimilars
    • Strong Government Support and Favorable Reimbursement Policies Propel Market Growth
    • Challenges
    • Development of Autoinjectors for Multiple Drug Viscosities: A Major Challenge
    • Increasing Demand for Alternative Drug Delivery Modes Hampers Market Growth
    • Emergence of Oral Diabetic Agents, Oral Insulin and Epinephrine Nasal Sprays Poses Huge Challenge for Autoinjectors Market
    • Product Overview
    • Autoinjector: Definition
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Anaphylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Anaphylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Anaphylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 22: Canada Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Canada Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: Canada 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 25: Japan Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Japan Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Japan 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 28: China Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: China Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: China 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 31: Europe Current & Future Analysis for Autoinjectors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe Historic Review for Autoinjectors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Europe 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 34: Europe Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 37: France Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: France Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: France 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 40: Germany Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Germany Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Germany 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 43: Italy Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Italy 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 46: UK Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: UK Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: UK 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 49: Spain Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Spain Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Spain 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 52: Russia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Russia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Russia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 55: Rest of Europe Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Rest of Europe Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Rest of Europe 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 58: Asia-Pacific Current & Future Analysis for Autoinjectors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Asia-Pacific Historic Review for Autoinjectors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Asia-Pacific 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 61: Asia-Pacific Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Asia-Pacific 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 64: Australia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Australia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Australia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 67: India Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: India Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: India 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 70: South Korea Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: South Korea Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: South Korea 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 73: Rest of Asia-Pacific Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Rest of Asia-Pacific Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Rest of Asia-Pacific 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 76: Latin America Current & Future Analysis for Autoinjectors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 77: Latin America Historic Review for Autoinjectors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Latin America 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 79: Latin America Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Latin America Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Latin America 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 82: Argentina Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Argentina Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Argentina 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 85: Brazil Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Brazil Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Brazil 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 88: Mexico Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Mexico Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Mexico 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 91: Rest of Latin America Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Latin America Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Latin America 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 94: Middle East Current & Future Analysis for Autoinjectors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 95: Middle East Historic Review for Autoinjectors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Middle East 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 97: Middle East Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Middle East Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Middle East 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 100: Iran Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Iran Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Iran 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 103: Israel Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Israel Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Israel 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 106: Saudi Arabia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Saudi Arabia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Saudi Arabia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 109: UAE Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UAE Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: UAE 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 112: Rest of Middle East Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Rest of Middle East Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Rest of Middle East 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 115: Africa Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Africa Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Africa 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42